ImmunoPrecise Antibodies (IPA) Competitors $2.10 +0.17 (+8.55%) Closing price 09/3/2025Extended Trading$2.10 0.00 (0.00%) As of 09/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. CGEM, AURA, FULC, ADCT, AUTL, DMAC, MBX, BNTC, IMRX, and CTNMShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Cullinan Therapeutics (CGEM), Aura Biosciences (AURA), Fulcrum Therapeutics (FULC), ADC Therapeutics (ADCT), Autolus Therapeutics (AUTL), DiaMedica Therapeutics (DMAC), MBX Biosciences (MBX), Benitec Biopharma (BNTC), Immuneering (IMRX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Cullinan Therapeutics Aura Biosciences Fulcrum Therapeutics ADC Therapeutics Autolus Therapeutics DiaMedica Therapeutics MBX Biosciences Benitec Biopharma Immuneering Contineum Therapeutics ImmunoPrecise Antibodies (NASDAQ:IPA) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Which has higher valuation & earnings, IPA or CGEM? ImmunoPrecise Antibodies has higher revenue and earnings than Cullinan Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$17.59M5.50-$21.69M-$0.68-3.08Cullinan TherapeuticsN/AN/A-$167.38M-$3.23-1.96 Do analysts prefer IPA or CGEM? ImmunoPrecise Antibodies presently has a consensus target price of $4.00, indicating a potential upside of 90.93%. Cullinan Therapeutics has a consensus target price of $26.00, indicating a potential upside of 310.09%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cullinan Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is IPA or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -122.10%. Cullinan Therapeutics' return on equity of -36.56% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-122.10% -40.62% -22.19% Cullinan Therapeutics N/A -36.56%-34.82% Does the media prefer IPA or CGEM? In the previous week, Cullinan Therapeutics had 3 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 5 mentions for Cullinan Therapeutics and 2 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.85 beat Cullinan Therapeutics' score of 0.57 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunoPrecise Antibodies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IPA or CGEM? ImmunoPrecise Antibodies has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Do institutionals & insiders have more ownership in IPA or CGEM? 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryCullinan Therapeutics beats ImmunoPrecise Antibodies on 8 of the 15 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.68M$2.17B$5.78B$10.28BDividend YieldN/AN/A5.74%4.64%P/E Ratio-3.0838.4976.9426.98Price / Sales5.5010.59543.88128.54Price / CashN/A56.7037.1760.63Price / Book5.6611.6113.836.37Net Income-$21.69M-$64.84M$3.29B$271.46M7 Day PerformanceN/A-0.09%1.57%2.53%1 Month Performance-18.48%2.77%6.87%9.42%1 Year Performance212.69%34.06%81.59%30.16% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.564 of 5 stars$2.10+8.5%$4.00+90.9%+217.4%$96.68M$17.59M-3.0880Gap UpCGEMCullinan Therapeutics2.345 of 5 stars$6.35-2.8%$27.67+335.7%-63.2%$385.76MN/A-1.9730Positive NewsAnalyst UpgradeAURAAura Biosciences2.1127 of 5 stars$5.97-3.4%$22.00+268.5%-34.5%$383.90MN/A-3.0550Positive NewsFULCFulcrum Therapeutics2.6433 of 5 stars$7.07+1.0%$9.60+35.8%+119.2%$378.64MN/A-5.80100Positive NewsADCTADC Therapeutics2.9055 of 5 stars$3.21-3.2%$7.75+141.8%+9.9%$372.37M$70.84M-2.04310AUTLAutolus Therapeutics3.8066 of 5 stars$1.32-4.3%$9.12+590.9%-64.9%$367.28M$29.93M-1.57330Short Interest ↓DMACDiaMedica Therapeutics2.0518 of 5 stars$7.01-1.1%$12.33+75.9%+63.7%$366.48MN/A-10.1620MBXMBX Biosciences2.669 of 5 stars$10.87+0.4%$37.63+246.1%-52.0%$363.82MN/A-2.3936Positive NewsBNTCBenitec Biopharma1.2442 of 5 stars$13.70-1.1%$26.00+89.8%+67.3%$363.57M$80K-9.0720News CoveragePositive NewsUpcoming EarningsAnalyst ForecastIMRXImmuneering3.3317 of 5 stars$7.86-7.4%$13.75+74.9%+295.2%$352.93M$320K-4.1660CTNMContineum Therapeutics2.5816 of 5 stars$12.39+0.3%$22.75+83.6%-32.9%$346.46M$50M-5.6331Short Interest ↑ Related Companies and Tools Related Companies Cullinan Therapeutics Alternatives Aura Biosciences Alternatives Fulcrum Therapeutics Alternatives ADC Therapeutics Alternatives Autolus Therapeutics Alternatives DiaMedica Therapeutics Alternatives MBX Biosciences Alternatives Benitec Biopharma Alternatives Immuneering Alternatives Contineum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPA Stock Alerts